Aeolus's Antioxidant Found Effective Against Mustard Gas Exposure
Posted on: Friday, 25 April 2008, 00:00 CDT
Aeolus Pharmaceuticals has reported that researchers from the National Jewish Research and Medical Center and the University of Colorado have completed a series of studies demonstrating that AEOL 10150 provides statistically significant protection of the lungs and skin in the 2-chloroethyl-ethylsulfide model of mustard gas exposure in rats.
The primary objective of this study was to determine whether administration of AEOL 10150, a patented, small molecule catalytic antioxidant, reduces the severity of acute lung injury induced by mustard gas exposure. AEOL 10150 was given to rats one hour after CEES (2-chloroethyl-ethylsulfide) exposure and again nine hours later. Eighteen hours after exposure, lung edema and hemorrhage were assessed by changes in the bronchoalveolar lavage protein and red blood cell levels.
AEOL 10150 significantly reduced (p<0.05) mustard gas-induced lung edema and hemorrhage as measured by bronchoalveolar lavage lactate dehydrogenase activity, protein levels, IgM levels and cellularity. These results indicate that AEOL 10150 rescues the lung from mustard gas exposure and may provide an effective countermeasure against mustard gas-induced lung injury.
Another primary objective of this study was to determine whether administration of AEOL 10150 reduces the severity of skin injury induced by mustard gas exposure. AEOL 10150 was given to hairless mice (topically) one hour after CEES exposure and again nine hours later. Eighteen hours after exposure, skin damage was assessed by changes in skin fold thickness. These results suggest that topical application of AEOL 10150 rescues the skin from CEES-induced skin injury and may provide an effective countermeasure against mustard gas-induced skin injury.
Source: Datamonitor
Related Articles
- Aeolus Initiates Phase I Amyotrophic Lateral Sclerosis Study
- Aeolus Pharmaceuticals Announces Initiation of Multiple Dose Study of AEOL 10150 in a Patient With ALS
- Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential to Accelerate Recovery of Bone Marrow Stem Cells Following Cancer Radiation Therapy
- Aeolus Pharmaceuticals' AEOL 10150 Highlighted in Nature Genetics Publication
- Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150
- Aeolus Pharmaceuticals Announces Completion of Dosing of First Multiple Dose Cohort of AEOL 10150 in ALS Patients
- Aeolus Pharmaceuticals Announces Initiation of Multiple Dose Study of AEOL 10150 in Patients With Lou Gehrig's Disease.
- Protection of Normal Tissue From Radiation-Induced Injury Using AEOL 10150 Presented at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology
- Aeolus Pharmaceuticals, Inc. Announces Publication of Results of AEOL 10150 Studies in Annals of Neurology
User Comments (0)

RSS Feeds